Julie Maréchal-Jamil: The Biosimilars Market in Europe

Julie Maréchal-Jamil, director of biosimilars policy and science at Medicines for Europe, describes the state of the EU biosimilars market.
July 10, 2019


So I think what’s very important to notice is that biosimilars are used everywhere, in every country. And I think this is important; we’ve had 28 countries until now, and I think it's important to see they are used by every healthcare system. 

The nuance in there is that they are used in a variable fashion. So between countries you see a massive difference, and within countries you also see massive differences between the different biosimilars available.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.